MarginsXMarginsX
Home › Markets › Health Care › PGEN

Precigen Inc. (PGEN)

PGEN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$4.30
-5.29% on the day
Market cap
$1.5B
Small cap
Revenue · 2025
$9.7M
+146.7% on 2024
Net income · 2025
-$250.6M
-2588.2% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1356090/000135609026000009/0001356090-26-000009-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerPGEN on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001356090
SEC industry codePharmaceutical Preparations
Incorporated inVA

Financials · 2025

LineValue
Revenue$9.7M
Net income-$250.6M
Operating income-$110.5M
Net margin-2588.2%
Operating margin-1141.1%
Revenue growth+146.7%
Cash$30.2M
Total assets$155.5M
P/E (computed)Net income was not positive
P/S (computed)159.2×

Warning signs

Cash runway
2.5 months
$15.0M cash at September 30, 2026
Share count, 1 year
+1.3%
2025-10-31 to 2026-10-30 · +44.0% over 3 years
Going-concern doubt
No
10-Q filed November 4, 2026
Insider net buying, 12 months
-$44.5M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-04
Cash and burn$15.0M cash; operating cash flow -$18.3M a quarter.Report 2026-09-30
Shares outstanding358,549,980 (2026-10-30); 353,824,499 a year earlier; 248,919,096 three years earlier.Cover page 2026-10-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDeloitte & Touche LLP, Baltimore, Maryland, United StatesPCAOB Form AP 2026-04-01
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $25K, sold $44.6M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$74.1M$35.8M$11.9M$15.0M$94.3M$156.9M10-Q 2026-11-04
Q2 2026
2026-06-30
$55.0M$20.1M-$17.8M$16.3M$93.9M$85.7M10-Q 2026-08-04
Q1 2026
2026-03-31
$23.3M-$7.9M-$43.8M$7.5M$93.5M$31.6M10-Q 2026-05-13
Q4 2025
2025-12-31
$4.6M-$23.5M-$23.5M$30.2M$93.2M$9.7M10-K 2026-03-25
Q3 2025
2025-09-30
$2.9M-$146.3M-$29.1M$14.3M$92.9MNeeds four quarters10-Q 2026-11-04
Q2 2025
2025-06-30
$856K-$26.6M-$19.0M$13.8MNo debt tagsNeeds four quarters10-Q 2026-08-04
Q1 2025
2025-03-31
$1.3M-$54.2M-$16.3M$6.1MNo debt tagsNeeds four quarters10-Q 2026-05-13
Q4 2024
2024-12-31
Not filed-$19.7M-$8.2M$29.5M$0$3.9M10-K 2026-03-25

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
FORM S-3
S-32025-08-19
Latest annual report10-K2026-03-25
Latest quarterly / interim10-Q2026-11-04
Latest current report
FORM 8-K
8-K2026-11-05
Latest proxyDEFA14A2026-04-30

Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+1.6%
1 month-39.3%
3 months-30.0%
Year to date+8.6%
1 year+17.6%
From 52-week high-47.0%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
QUREuniQure N.V.$21.88-8.11%$1.5B
ADRXADARx Pharmaceuticals Inc.$14.00-1.41%$1.6B
SLSSELLAS Life Sciences Group Inc.$7.47-4.96%$1.5B
KRSAKorsana Biosciences Inc.$32.68+3.25%$1.5B
NRIXNurix Therapeutics Inc.$14.73-4.84%$1.6B
ANIPANI Pharmaceuticals Inc.$70.89-0.77%$1.6B
RAPPRapport Therapeutics Inc.$24.82-5.09%$1.5B
RAREUltragenyx Pharmaceutical Inc.$15.90-1.12%$1.6B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier